Categories Technology

Coupa Software Q2 earnings: What’s on the cards

Coupa Software (NASDAQ: COUP), a technology firm with a focus on Business Spend Management, is slated to report second-quarter 2020 financial results after the closing bell on Tuesday, September 3.

Wall Street expects to see continued growth in top-line, helped by the strength in subscriber revenues. Analysts expect the San Mateo, California-based firm to report a 38.5% increase in revenues to $85.38 million.

The analysts’ expectation falls within the management projection range of Q2 revenues between $84.5 million and $85.5 million. The management had also projected subscription revenues in the range of $77-78 million.

READ: Nutanix beats the market in Q4, stock jumps

For the second quarter, the management expects an adjusted loss of 10-12 cents per share. The street estimate is pegged at the lower end of this projection range at 10 cents per share loss. In three of the past four quarters, the software company had surpassed Wall Street projections on the bottom-line, while it was in line with the estimate once.

Coupa had recently forged partnerships with PayPal (NASDAQ: PYPL) and Citigroup (NYSE: C) with a focus on making business payments more efficient. The company had also last month acquired contract lifecycle management solutions firm Exari to integrate into its BSM platform. Look out for any updates on how these alliances are working out financially for the firm.

READ: Hewlett Packard Enterprise beats Q3 EPS by 5 cents

Coupa had an exceptionally good year so far, with its stock soaring 126% in the year-to-date period. During the same period, the iShares Expanded Tech-Software ETF has gained just 24%.

Coupa is currently trading near its 12-month price target, so a post-earnings rally may be unlikely.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of

Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings

Goldman Sachs (GS) stock research summary | Q3 2021

Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top